



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Hepatology

**ESPS Manuscript NO:** 9589

**Title:** Febrile neutropenia degree 4 and Fournier’s Syndrome associated with triple therapy for HCV: a case report

**Reviewer code:** 00092173

**Science editor:** Xiu-Xia Song

**Date sent for review:** 2014-02-20 15:55

**Date reviewed:** 2014-03-03 22:11

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

Dr. Oliveira and colleagues presented an interesting case report in which they aimed to report on a case of febrile neutropenia and the suspicion of Forunier's syndrome in a patient with chronic HCV infection under triple therapy with PEG-IFN/RBV/BOC. Although a number of adverse events have been reported for treatment of chronic HCV with IFN, RBV, boceprevir (BOC) and telaprevir (TVR), the reported complication with the triple therapy IFN/RBV/BOC has not been reported so far. Overall, the study is well performed and the data are concise in its content; however, there are some limitations which should be addressed. In general, there are a number of typing errors (e.g. peg-interferon not peguinterferon) and the English spelling and grammar should be checked carefully, possibly by a native English speaker. Comments 1) Page 2: The term “null non-responder” should be described 2) Case Report, page 3. The clinical data and the case history of the patient should be given in more detail, e.g., what kind of treatment for how long the patient received. Possible alcohol abuse, other medication and so on. 3) Page 3. What is “mcg”? 4) Case report, page 3, third para. Did the patient achieve >1,000neurtophils/mm3? 5) The CT data should be described in more detail. 6) Is there an ethical review on hand, or is this not needed in this case report? 7) A clear statement at the end of the discussion section is missing.